Ear­ly da­ta on NextCure's im­muno-on­col­o­gy drug in lung can­cer pa­tients de­lights in­vestors

Shares of fresh­ly pub­lic biotech NextCure sky­rock­et­ed on Tues­day af­ter the com­pa­ny pub­lished an ab­stract high­light­ing ini­tial da­ta from an ear­ly-stage study of its sole ex­per­i­men­tal im­muno-on­col­o­gy drug.

The ther­a­py, NC318, is en­gi­neered to in­hib­it Siglec-15 (S15), a key im­mune sup­pres­sor in cer­tain can­cer pa­tients whose tu­mors are re­sis­tant to the ex­ist­ing raft of check­point in­hibitors. S15 is found on cer­tain myeloid cells in the tu­mor mi­croen­vi­ron­ment and on cer­tain tu­mor types in­clud­ing lung, ovar­i­an and head, and neck can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA